Trading-Stocks.de

Healthcare | Drugs - Generic | USA
Allergan Tumbles After Swinging to Fourth-Quarter Loss

Botox maker reports a fourth-quarter loss of $4.3 billion, a reversal from a year-earlier profit of $3.05 billion.^

Allergan PLC (AGN - Get Report)  fell 7.8% Tuesday after the pharmaceuticals giant reported a $4.3 billion loss in the fourth quarter, a reversal from a year-earlier profit of $3.05 billion.

The Dublin-based maker of Botox and other specialty medications and procedures shed as much as $11.28, or 8.8%, to $144.75 after the firm posted a loss of $12.83 a share for the quarter. Adjusted for one-time gains and costs, the company posted per-share earnings of $4.29 a share, above analysts' expectations of $4.15.

..

https://www.thestreet.com/investing/alle...yptr=yahoo

na ja, auch an Allergan nagt Zahn der Zeit - die Aktien könnten auf jeden Fall ne'n Schuss Botox gut gebrauchen

Allergan stock falls after depression study fails

Allergan PLC AGN, shares declined in after-hours trading Wednesday after the pharmaceutical giant announced that a major study of one of its candidates on major depressive disorder did not produce the desired results. 

...

https://www.marketwatch.com/story/allerg...latestnews

AGN runde 5% nachbörslich runter...

Allergan Tops Q1 Earnings Estimate, Boosts Full-Year Profit Outlook

Allergan posted stronger-than-expected first quarter earnings Tuesday, and boosted its full-year profit guidance, as Botox sales continue to drive top-line growth for the Dublin-based pharmaceutical group.

...

Allergan said adjusted non-GAAP earnings for the three months ending in March came in at $3.79 per share, up 1.3% from the same period last year and well ahead of the Street consensus of $3.55 cents per share. Group revenues, the company said, rose 2% to $3.6 billion, edging just past analysts' forecasts of $3.57 billion.

...

https://www.thestreet.com/investing/earn...yptr=yahoo

laut WSJ wird Allergan (AGN) von AbbVie (ABBV) für mehr als $ 60 Mrd geschluckt, resp. für $188.-- pro AGN in cash & stock
closing AGN gestern: $129.6

Was die ABBV-Aktie gerade mit -11% quittiert, kostet mich nur nen 1000'er 

jf2 schrieb:Was die ABBV-Aktie gerade mit -11% quittiert, kostet mich nur nen 1000'er 

wieso auch ein Pharmariese kaufen, dessen Umsatzstärkste Produkt (Humira) kurz vor Ablauf seines Patents steht......
weil halt die grossen Pharmaunternehmen immer weniger aussichtsreiche neue Medikamente in iher eigenen Pipeline haben, kaufen's halt immer mehr zu
(siehe auch z.B.  Pfizer letzte Woche mit Kauf von ArrayBioPharma)

(25.06.2019, 16:12)F.I.A.S.C.O. schrieb: [ -> ]wieso auch ein Pharmariese kaufen, dessen Umsatzstärkste Produkt (Humira) kurz vor Ablauf seines Patents steht......
weil halt die grossen Pharmaunternehmen immer weniger aussichtsreiche neue Medikamente in iher eigenen Pipeline haben, kaufen's halt immer mehr zu
(siehe auch z.B.  Pfizer letzte Woche mit Kauf von ArrayBioPharma)

Es spricht ja auch an sich nichts gegen diversification acquisition. Das machen in anderen Bereichen ja auch viele Große. Schau dir die Consumer Giants an.

Wenn das inhaltlichen und finanziellen Sinn macht, stört mich das bei meinen Unternehmen nicht.

Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up

Allergan plc’s AGN second-quarter adjusted earnings came in at $4.38 per share, which beat the Zacks Consensus Estimate of $4.34 and came within the guided range of $4.20 and $4.40. Earnings however declined 0.9% year over year due to lower operating profits.

Revenues came in at $4.09 billion, which exceeded the Zacks Consensus Estimate of $3.94 billion as well as the guidance of $3.88 billion to $4.03 billion. Revenues fell 0.8% from the year-ago period primarily due to currency headwinds. Excluding the impact of currency, total revenues rose 1.2% as higher sales of key products like Botox (cosmetic and therapeutics), Juvéderm collection of fillers, Vraylar, Ozurdex, and Lo Loestrin made up for the loss of exclusivity on some brands and divestitures of some others in 2018.


...

https://finance.yahoo.com/news/allergan-...02803.html